Literature DB >> 2525143

Tolerance induction of allo-class I H-2 antigen-reactive Lyt-2+ helper T cells and prolonged survival of the corresponding class I H-2-disparate skin graft.

T Azuma1, S Sato, S Kitagawa, S Hori, S Kokudo, T Hamaoka, H Fujiwara.   

Abstract

C57BL/6 (B6) mice were i.v. presensitized with class I H-2-disparate B6-C-H-2bm1 (bm1) spleen cells. Such presensitization resulted in almost complete abrogation of bm1-specific Lyt-2+ T cell-mediated proliferative and IL-2-producing capacities as measured by MLC of lymphoid cells from presensitized B6 mice with stimulating bm1 cells. In contrast, comparable magnitude of CTL responses was generated in bulk cultures from presensitized B6 lymphoid cells to that obtained in unpresensitized B6 responding cultures. These differential influences of Lyt-2+ T cell functions were also demonstrated by limiting dilution assays; frequencies of proliferative and IL-2-producing T cell precursors were as low as undetectable in presensitized B6 lymphoid cells, whereas an appreciable frequency of CTL precursors in a portion of the same lymphoid cells was observed. When bm1 skin grafting was performed in B6 mice i.v. presensitized with bm1 cells, the strikingly prolonged survival of bm1 skin grafts was observed. It was also demonstrated that the bm1 skin graft-bearing B6 mice which had been presensitized with bm1 cells not only exhibited a continuing suppressive state of bm1-specific helper (proliferative and IL-2-producing) function but also failed to generate anti-bm1 CTL responses. These results indicate that 1) i.v. presensitization with class I H-2 alloantigens results in selective tolerance of Lyt-2+ Th cells which is adequate for inducing prolonged graft survival, 2) the induction of complete abrogation of CTL potential is not absolute requirement for the prolongation of graft survival, and 3) residual CTL potential is attenuated after grafting so far as Th cells are rendered tolerant.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2525143

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  Partial tolerance of subcutaneously transplanted xenogeneic tumour cell graft by Fas-mediated immunosuppression.

Authors:  T Sawada; T Koji; Y Hishikawa; K Kishimoto; T Nagayasu; T Takahashi; T Oka; H Ayabe
Journal:  Immunology       Date:  2001-05       Impact factor: 7.397

2.  Induction of anti-allo-class I H-2 tolerance by inactivation of CD8+ helper T cells, and reversal of tolerance through introduction of third-party helper T cells.

Authors:  S Kitagawa; S Sato; S Hori; T Hamaoka; H Fujiwara
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

3.  Superantigen-based tumor therapy: in vivo activation of cytotoxic T cells.

Authors:  G Hedlund; M Dohlsten; C Petersson; T Kalland
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

4.  Specific CTL activity of CD8+ TCR Vbeta14+ T cell in mouse 2, 4, 6-trinitrobenzene sulfonic acid-induced colitis.

Authors:  Toyoo Nitta; Hisashi Iwata; Yoshio Mori; Hisato Takagi; Toshio Hirota; Kazuto Kanetake; Yutaka Iida; Ken-Ichi Sakamoto; Takuya Yamada; Masanao Saio; Hajime Hirose
Journal:  Dig Dis Sci       Date:  2003-10       Impact factor: 3.199

5.  Heterogenous graft rejection pathways in class I major histocompatibility complex-disparate combinations and their differential susceptibility to immunomodulation induced by intravenous presensitization with relevant alloantigens.

Authors:  S Kitagawa; H Iwata; S Sato; J Shimizu; T Hamaoka; H Fujiwara
Journal:  J Exp Med       Date:  1991-09-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.